OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe for subcutaneous injection in the U.S. The availability of the first omalizumab biosimilar introduces an additional […]
Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion’s commitment to elevating the standard of care and addressing unmet medical need in gastroenterology INCHEON, South […]
– AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States – The launch of AVTOZMA SC further diversifies Celltrion’s immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated inflammatory diseases INCHEON, South Korea, March 16, […]
– Celltrion outlines a blueprint for innovative drug development built on its antibody expertise – The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 2026 /PRNewswire/ — Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today presented key strategic priorities […]
INCHEON, South Korea, Jan. 6, 2026 – Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer and Hyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 12–15, 2026. Celltrion’s presentation and fireside chat are scheduled for Tuesday, January […]
– FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases – OMLYCLO® (omalizumab-igec) is the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab); The FDA previously approved OMLYCLO® 75 mg/0.5 mL and 150 mg/mL in […]